- Oops!Something went wrong.Please try again later.
DORAL, Florida, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, reviews the Company’s 2018 achievements and shares what’s to come in 2019.
During the fiscal first quarter, the Company expanded its executive team with the appointment of Jill Buzan as a new Chief Sales Officer (CSO) and Wendell Hecker as Chief Financial Officer (CFO). Since the first of the year, under Buzan and Hecker’s leadership, sales have increased over 100 percent. The Company has also become fully reporting, employing accurate bookkeeping throughout the process.
At the end of Q1, the Company appointed a new chief operating officer (COO), while Nickolas S. Tabraue, the COO at the time, continued as President, Director and Chairman to focus on the company’s expansion. Since the addition of Gagan Hunter as COO, the Company has increased inventory control accuracy, which has assisted in the full reporting process and made company audits easier, ultimately helping the company achieve a smooth transition as it grows.
During the fiscal second quarter, the Company added a pharmacist & LP3 as Chief of Pharmacy, furthering efforts to obtain a license to distribute controlled substances. Since Jad Nammour joined the Company, he has assisted in the development of the Company’s CBD nutraceutical-based IPs and medical device.
During the fiscal third quarter, the Company achieved fully reporting status with the SEC under the exchange act of 1934. Since achieving fully reporting status and with the resulting increased transparency, the Company has been able to obtain more direct and retail investors.
In the middle of Q3, the Company officially uplisted to the OTCQB Exchange, operating as a OTCQB Company with fully reporting status. This status has positioned the Company to a higher standard, providing a strong baseline for transparency as well as technology and regulations that improve the flow of information and trading experience for investors. U.S. investors can find current financial disclosure and real-time level2 quotes for ETST.
At the end of Q3, the Company initiated a DRTV media campaign with former Shark Tank star Kevin Harrington’s award-winning As Seen On TV production company. Production on the campaign has begun and the Company anticipates a Q2019 launch date. The campaign being created for ETST will include:
·A 60-second DRTV commercial spot to be aired 300 times within 10 selected regions and selected networks.
·A 15-second promotional video to be used for digital and social media purposes.
·A featured placement on the website for 13 months
·Complete licensing rights to the commercial spot and promotional video, and permission to use the world famous As Seen On TV logo on ETST’s products.
During the fiscal fourth quarter, the Company’s partnership with Bionatus is almost market ready.
A major Q4 achievement was the Company’s first commercial production run of Hygee(TM) medical device kits that easily test for chlamydia. Hygee™ anticipates strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee™ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. These numbers are supported by the fact that chlamydia is a global issue; that the company’s network of distributors is worldwide; and that the thin structure of the device and the stability of the specimen collected with Hygee™ ensures that it can be easily dispersed on all continents.
At the end of Q4, the Company engaged counsel with Canadian Securities Exchange (CSE) expertise to assist with dual listing. Listing could happen as early as in the third quarter of the Company’s current fiscal year and would require certain regulatory approvals that would allow Earth Science to market and sell its common shares to Canadian investors.
ETST Management Reviews 2018, Looks Ahead
“In 2018, we made sufficient changes to i mprove our point of sale system, inventory and accounting management systems, improved on our manufacturing and packaging, strengthened the potency and effectiveness of our products, and increased our sales I am confident with the implementation of these changes and the addition of our new CSO, David Barbash. The company will reach new heights in 2019 as we now focus on increasing and expanding our sales force and employ a new marketing team. As we increase our distribution and presence in the marketplace, 2019 will be the best year in the company's history.” - Gagan Hunter, COO & Director
“I am very proud of all the work of our team and partners in 2018. Together we have created a culture of creativity and an enormous potential of growth. With the launch of our new product lines and our ongoing program of research and development, I anticipate an incredible 2019 for the company. I am devoted to our shareholders interests, and to helping everyone on the planet who aspires to a better life through better health. I wish you all the very best for the year to come, and that you share the same kind of success as Earth Science Tech.” - Dr. Michel Aubé, CEO & Chief Science Officer
“There is a solid foundation to build on in 2019 here at ETST and with major distribution expansion planned in the New Year on the heels of the signing of the Farm Bill, I see a great reason to be enthused about actualizing the potential here.” – David Barbash,The Company’s new Chief Sales Officer
“In 2018 the Company became fully reporting, uplisted, improved our High Grade Full Spectrum line, increased sales over 100%, ordered our first batch of Hygee(TM) to launch early 2019, and engaged council to assist in the Canadian dual exchange. We are positioned to catapult during 2019. We have a solid executive team, company transparency, and everything is set. I truly look forward to the new year exceeding everyone’s expectations in company growth and revenue.” - Nickolas S. Tabraue, President, Director and Chairman
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Nickolas S. Tabraue
President, Director & Chairman